Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination With Erlotinib in Papillary Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 06 Mar 2017
At a glance
- Drugs Tivantinib (Primary) ; Erlotinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 09 May 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Apr 2017.
- 02 Jun 2015 Status changed from active, no longer recruiting to discontinued, according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.